Results 31 to 40 of about 97,507,719 (246)

Early vessel destabilization mediated by Angiopoietin-2 and subsequent vessel maturation via Angiopoietin-1 induce functional neovasculature after ischemia. [PDF]

open access: yes, 2013
We assessed whether Angiopoietin-2 (Ang2), a Tie2 ligand and partial antagonist of Angiopoietin-1 (Ang1), is required for early vessel destabilization during postischemic angiogenesis, when combined with vascular growth factors.
Di Qin (107446)   +27 more
core   +2 more sources

Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation

open access: yesFrontiers in Oncology, 2022
BackgroundThough the precise criteria for accessing LT are consistently being applied, HCC recurrence (HCC-R_LT) still affects more than 15% of the patients.
Simone Lasagni   +32 more
doaj   +1 more source

Serum angiopoietin-1 and -2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children. [PDF]

open access: yes, 2009
BACKGROUND: Limited tools exist to identify which individuals infected with Plasmodium falciparum are at risk of developing serious complications such as cerebral malaria (CM). The objective of this study was to assess serum biomarkers that differentiate
Hawkes, Michael   +38 more
core   +1 more source

ANGPTL3 affects the metastatic potential and the susceptibility of ovarian cancer cells to natural killer cell-mediated cytotoxicity

open access: yesHeliyon, 2023
High metastatic potential and resistance to immunotherapy lead to poor survival in patients with ovarian cancer. Angiopoietin-like protein 3 is aberrantly expressed and exerts diverse roles in the progression of several cancers.
Yuxian Wu, Yaqun Zheng, Zhijun Jin
doaj   +1 more source

Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure

open access: yesJournal of the American College of Cardiology, 2004
The goal of this research was to test the hypothesis that plasma angiopoietin (Ang-1), its soluble receptor tie-2, and Ang-2 levels would be abnormal in patients with acute and chronic congestive heart failure (CHF) when compared with healthy controls.Increased plasma vascular endothelial growth factor (VEGF) in CHF is suggestive of excess angiogenesis-
Chong, Aun Yeong   +4 more
openaire   +2 more sources

Circulating angiopoietin-2 is a marker for early cardiovascular disease in children on chronic dialysis.

open access: yesPLoS ONE, 2013
Cardiovascular disease (CVD) is increasingly recognised as a complication of childhood chronic kidney disease (CKD) even in the absence of diabetes and hypertension.
Rukshana C Shroff   +9 more
doaj   +1 more source

Female sex protects against renal edema, but not lung edema, in mice with partial deletion of the endothelial barrier regulator Tie2 compared to male sex.

open access: yesPLoS ONE, 2023
BackgroundThe endothelial angiopoietin/Tie2 system is an important regulator of endothelial permeability and targeting Tie2 reduces hemorrhagic shock-induced organ edema in males.
Anoek L I van Leeuwen   +8 more
doaj   +1 more source

New molecular mediators in tumor angiogenesis [PDF]

open access: yes, 2007
Angiogenesis is essential for tumor growth and progression. It has been demonstrated that tumor growth beyond a size 1 to 2 mm3 requires the induction of new vessels.
Jonas, Dietger   +2 more
core   +1 more source

Genetic variation implicates plasma angiopoietin-2 in the development of acute kidney injury sub-phenotypes

open access: yesBMC Nephrology, 2020
Background We previously identified two acute kidney injury (AKI) sub-phenotypes (AKI-SP1 and AKI-SP2) with different risk of poor clinical outcomes and response to vasopressor therapy.
Pavan K. Bhatraju   +17 more
doaj   +1 more source

sj-docx-1-vrd-10.1177_24741264221126061 – Supplemental material for Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial

open access: yes, 2022
Supplemental material, sj-docx-1-vrd-10.1177_24741264221126061 for Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial by Jeffrey S. Heier, Allen C. Ho, David S. Boyer, Karl Csaky, Robert Vitti,
Friedrich Asmus (14327961)   +12 more
core   +1 more source

Home - About - Disclaimer - Privacy